A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

NCT ID: NCT04152889

Last Updated: 2020-04-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-04-14
• Study Completion Date: 2022-12-31

Brief Summary

To evaluate the efficacy and safety of Camrelizumab in Combination With Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR) . Secondary study objective: To observe and evaluate the overall survival and adverse events of Camrelizumab in Combination With Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR). To evaluate the safety ofCamrelizumab in Combination With Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR). Objective: To explore the incidence of PD-L1 + / MSI-H / EBV + /dMMR in stage III gastric cancer. To explore the correlation of PD-L1 + / MSI-H / EBV + /dMMR in stage III gastric cancer.

Conditions

Gastric Cancer Stage III

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Camrelizumab+chemotherapy

Group Type: EXPERIMENTAL

Camrelizumab

Intervention Type: DRUG

Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.

S-1

Intervention Type: DRUG

Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.

Docetaxel

Intervention Type: DRUG

Docetaxel: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.

Interventions

Camrelizumab

Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.

Intervention Type: DRUG

S-1

Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.

Intervention Type: DRUG

Docetaxel

Docetaxel: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.

Intervention Type: DRUG

Other Intervention Names

SHR-1210

Eligibility Criteria

Inclusion Criteria

1. The patients voluntarily joined the study and signed the informed consent;

2. ≥ 18 years old, ≥ 80 years old, both male and female;

3. Stage III gastric cancer confirmed by pathology,

4. ECoG score: 0-1

5. Detection of biomarkers in postoperative gastric cancer samples suggests that: PD-L1 + CPS ≥ 10% / MSI-H + / EBV+/dMMR

6. No preoperative anti-tumor treatment for gastric cancer, including chemotherapy and local treatment

7. During the study treatment period and within 3 months after the end of the study treatment period, a medically recognized contraceptive measure (such as IUD, contraceptive pill or condom) should be used for the female patients of non-surgical sterilization or childbearing age; the serum or urine HCG test of the female patients of non-surgical sterilization must be negative within 72 hours before the study group; and the hCG test must be non lactation; for the male patients Sex, should be surgical sterilization, or agree to use appropriate methods of contraception during the trial and within 3 months after the last administration of the test drug.

8. The baseline blood routine and biochemical indexes of the selected patients should meet the following standards:

A. hemoglobin ≥ 90g / L

B. absolute neutrophil count ≥ 1.5 × 10 ^ 9 / L

C. platelet count ≥ 100 × 10 ^ 9 / L

D. ASTor ALT ≤ 2.5 ULN

E. Alkaline phosphatase (ALP)≤ 2.5×ULN

TSH ≤ 1 ULN (if abnormal, T3 and T4 levels should be examined at the same time, if T3 and T4 levels are normal, they can be included in the group);

Exclusion Criteria

1. Pregnant or lactating women;

2. Women of childbearing age were positive in the baseline pregnancy test;

3. Distant metastasis was diagnosed by CT /MR/ EUS.

4. Received previous anti-tumor treatment, including chemotherapy, radiotherapy or immunotherapy;

5. Have other malignant tumors in the past 5 years (except basal cell or squamous cell carcinoma, superficial bladder cancer, cervical cancer in situ or breast cancer);

6. Uncontrollable pleural effusion, pericardial effusion or ascites;

7. Severe cardiovascular diseases such as symptomatic coronary heart disease, congestive heart failure ≥ level II, uncontrolled arrhythmia and myocardial infarction within 12 months before admission;

8. With gastroduodenal obstruction/bleeding, digestive dysfunction or malabsorption syndrome

9. Complicated with severe uncontrolled concurrent infection or other serious uncontrolled concomitant diseases, moderate or severe renal injury;

10. Allergic reaction to the drugs used in this study;

11. Steroid or other systemic immunosuppressive therapy was used 14 days before admission;

12. Patients who received study drug treatment within 4 weeks before enrollment (participate in other clinical trials).

13. Active autoimmune diseases (including but not limited to: uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchodilator treatment). Subjects with hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia) can be selected.

14. History of primary immunodeficiency.

15. Immunosuppressive drugs were used within 4 weeks prior to the first dose of study treatment, excluding local or physiological doses of systemic glucocorticoids (i.e. no more than 10mg / day of prednisone or other glucocorticoids of equivalent dose) by nasal spray, inhalation or other routes, or hormones used to prevent allergy of contrast agents.

16. Receive live attenuated vaccine within 4 weeks before the first dose of study treatment or during the study period.

17. Active tuberculosis is known.

18. We have known the history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.

19. HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV DNA ≥ 10 ⁴ copies / ml; hepatitis C: HCV antibody and HCV-RNA positive, requiring antiviral treatment at the same time);.

20. Other factors that may affect the safety or test compliance of the subjects according to the judgment of the researchers. For example, serious diseases (including mental diseases) requiring combined treatment, serious laboratory abnormalities, or other family or social factors, etc.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RenJi Hospital

OTHER

Sponsor Role: lead

Responsible Party

zhaogang

Deputy director of gastrointestinal surgery administration

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Gang Zhao

Role: PRINCIPAL_INVESTIGATOR

RenJi Hospital, Shanghai JiaoTong University, School of Medicine Shanghai, Shanghai, China, 200127

Locations

Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University

Shanghai, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Gang Zhao

Role: CONTACT

zhaogang74313@aliyun.com

0086-021-68383731

Facility Contacts

Gang Zhao

Role: primary

zhaogang74313@aliyun.com

0086-021-68383731

Other Identifiers

ZG IIIS

Identifier Type: -

Identifier Source: org_study_id